Nuvo says new research shows Pennsaid safe

By Ted A. Knutson

Washington, March 1 - Nuvo Research Inc. said Wednesday an initial analysis of the data in its phase 3 long-term, open-label safety trial for Pennsaid has confirmed the safety of the experimental drug as suggested in earlier research.

Pennsaid is a topical non-steroidal anti-inflammatory (Nsaid) used for the treatment of osteoarthritis and is approved for sale in Canada and several European countries.

"The full analysis of data from this trial is still underway and we anticipate will be completed in the next 4-6 weeks," said Dr. Henrich Guntermann, Nuvo's president and chief executive officer, in a press release. "The results of this study will form part of our [New Drug Application] submission for Pennsaid, which remains on schedule for mid 2006."

The trial involved more than 300 patients who were administered Pennsaid for 26 weeks and a subset of more than 100 of these patients who were administered the drug for a total of 52 weeks.

Markham, Ont.-based Nuvo is focused on developing innovative site-specific therapeutics that are delivered topically using the company's skin-penetrating technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.